Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
Public ClinicalTrials.gov record NCT05836220. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dose-Titrated PLS240 in the Treatment of Secondary Hyperparathyroidism in Individuals With End Stage Kidney Disease on Hemodialysis (PATH-2) With an Open-Label Extension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they will receive dose-titrated PLS240 for an additional 26 weeks. Throughout the duration of the study, patients will be expected to attend multiple study visits where an investigator will collect blood, preform electrocardiograms (ECGs) and physical exams, and further assess the safety and efficacy of PLS240.
Study identification
- NCT ID
- NCT05836220
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 412 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 15, 2023 (Actual)
- Primary completion
- Aug 5, 2025 (Actual)
- Completion
- Aug 5, 2025 (Actual)
- Last update posted
- Sep 9, 2025
2023 – 2025
United States locations
- U.S. sites
- 50
- U.S. states
- 20
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Number: USA039-2 | Anaheim | California | 92801-6731 | — |
| Site Number: USA001-2 | Chula Vista | California | 91910-3813 | — |
| Site Number: USA020-2 | Escondido | California | 92025-4402 | — |
| Site Number: USA042-2 | Fresno | California | 93720-3389 | — |
| Site Number: USA034-2 | Fullerton | California | 92832-3037 | — |
| Site Number: USA046-2 | Glendale | California | 91205-3313 | — |
| Site Number: USA019-2 | Granada Hills | California | 91344-7407 | — |
| Site Number: USA005-2 | La Mesa | California | 91942-3017 | — |
| Site Number: USA044-2 | Lancaster | California | 93534-2831 | — |
| Site Number: USA030-2 | Los Angeles | California | 90022-4302 | — |
| Site Number: USA043-2 | Los Angeles | California | 90033 | — |
| Site Number: USA022-2 | Moorpark | California | 93021-3352 | — |
| Site Number: USA049-2 | Northridge | California | 91324-2927 | — |
| Site Number: USA033-2 | Northridge | California | 91324-3528 | — |
| Site Number: USA003-2 | San Diego | California | 92111-3636 | — |
| Site Number: USA018-2 | San Dimas | California | 91773-3539 | — |
| Site Number: USA056-2 | Tarzana | California | 91356-2806 | — |
| Site Number: USA021-2 | Tarzana | California | 91356-3647 | — |
| Site Number: USA052-2 | Victorville | California | 92395-8322 | — |
| Site Number: USA023-2 | Arvada | Colorado | 80002-3714 | — |
| Site Number: USA031-2 | Aurora | Colorado | 80045-7202 | — |
| Site Number: USA017-2 | Middlebury | Connecticut | 06762-2843 | — |
| Site Number: USA015-2 | Newark | Delaware | 19713-2081 | — |
| Site Number: USA004-2 | Fort Myers | Florida | 33908-4154 | — |
| Site Number: USA002-2 | Hollywood | Florida | 33024-2776 | — |
| Site Number: USA041-2 | Orlando | Florida | 32801 | — |
| Site Number: USA035-2 | South Miami | Florida | 33143-5522 | — |
| Site Number: USA013-2 | Columbus | Georgia | 31904-3603 | — |
| Site Number: USA028-2 | Mishawaka | Indiana | 46545-3519 | — |
| Site Number: USA024-2 | Wichita | Kansas | 67214-2944 | — |
| Site Number: USA054-2 | New Orleans | Louisiana | 70112 | — |
| Site Number: USA048-2 | Detroit | Michigan | 48236-2169 | — |
| Site Number: USA025-2 | Kalamazoo | Michigan | 49007-3889 | — |
| Site Number: USA016-2 | Minneapolis | Minnesota | 55404-1212 | — |
| Site Number: USA007-2 | Amherst | New York | 14228-2792 | — |
| Site Number: USA053-2 | Charlotte | North Carolina | 28208-3876 | — |
| Site Number: USA026-2 | Durham | North Carolina | 27704-2147 | — |
| Site Number: USA009-2 | Toledo | Ohio | 43606-1171 | — |
| Site Number: USA045-2 | Roseburg | Oregon | 97471-6214 | — |
| Site Number: USA010-2 | Greenville | South Carolina | 29605-4019 | — |
| Site Number: USA027-2 | Knoxville | Tennessee | 37923-3624 | — |
| Site Number: USA011-2 | El Paso | Texas | 79925-4828 | — |
| Site Number: USA029-2 | Live Oak | Texas | 78233-4767 | — |
| Site Number: USA055-2 | Prosper | Texas | 75078-1411 | — |
| Site Number: USA012-2 | San Antonio | Texas | 78221-3019 | — |
| Site Number: USA008-2 | San Antonio | Texas | 78251-4125 | — |
| Site Number: USA006-2 | Waxahachie | Texas | 75165-1399 | — |
| Site Number: USA038-2 | St. George | Utah | 84790-5898 | — |
| Site Number: USA051-2 | Fairfax | Virginia | 22033-1907 | — |
| Site Number: USA037-2 | Norfolk | Virginia | 23507-1901 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05836220, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05836220 live on ClinicalTrials.gov.